| |
著者: Werner Kempf, Katrin Pfaltz, Maarten H Vermeer, Antonio Cozzio, Pablo L Ortiz-Romero, Martine Bagot, Elise Olsen, Youn H Kim, Reinhard Dummer, Nicola Pimpinelli, Sean Whittaker, Emmilia Hodak, Lorenzo Cerroni, Emilio Berti, Steve Horwitz, H Miles Prince, Joan Guitart, Teresa Estrach, José A Sanches, Madeleine Duvic, Annamari Ranki, Brigitte Dreno, Sonja Ostheeren-Michaelis, Robert Knobler, Gary Wood, Rein Willemze
雑誌名: Blood. 2011 Oct 13;118(15):4024-35. doi: 10.1182/blood-2011-05-351346. Epub 2011 Aug 12.
Abstract/Text
Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30(+) LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30(+) LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30(+) LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30(+) LPDs.
PMID 21841159 Blood. 2011 Oct 13;118(15):4024-35. doi: 10.1182/blood-2011-05-351346. Epub 2011 Aug 12.
|
